Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 78.05 Billion KRW | 27.44% |
| 2022 | 61.24 Billion KRW | 45.52% |
| 2021 | 42.08 Billion KRW | 3.67% |
| 2020 | 40.6 Billion KRW | -16.13% |
| 2019 | 48.41 Billion KRW | -21.48% |
| 2018 | 61.65 Billion KRW | -8.04% |
| 2017 | 67.04 Billion KRW | -0.62% |
| 2016 | 67.46 Billion KRW | 9.26% |
| 2015 | 61.74 Billion KRW | -1.73% |
| 2014 | 62.82 Billion KRW | 0.03% |
| 2013 | 62.8 Billion KRW | -18.6% |
| 2012 | 77.16 Billion KRW | 13.15% |
| 2011 | 68.19 Billion KRW | -0.59% |
| 2010 | 68.59 Billion KRW | -4.02% |
| 2009 | 71.46 Billion KRW | -10.52% |
| 2008 | 79.87 Billion KRW | 1.32% |
| 2007 | 78.83 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 15.98 Billion KRW | -27.41% |
| 2024 Q2 | 17.14 Billion KRW | 7.24% |
| 2023 FY | 78.05 Billion KRW | 27.44% |
| 2023 Q1 | 17.92 Billion KRW | 4.56% |
| 2023 Q4 | 22.02 Billion KRW | 21.84% |
| 2023 Q3 | 18.07 Billion KRW | -9.76% |
| 2023 Q2 | 20.02 Billion KRW | 11.7% |
| 2022 Q1 | 15.06 Billion KRW | 19.85% |
| 2022 Q3 | 15.98 Billion KRW | 22.57% |
| 2022 Q4 | 17.14 Billion KRW | 7.24% |
| 2022 Q2 | 13.04 Billion KRW | -13.42% |
| 2022 FY | 61.24 Billion KRW | 45.52% |
| 2021 Q4 | 12.57 Billion KRW | 18.54% |
| 2021 FY | 42.08 Billion KRW | 3.67% |
| 2021 Q1 | 8.78 Billion KRW | -13.97% |
| 2021 Q2 | 10.12 Billion KRW | 15.19% |
| 2021 Q3 | 10.6 Billion KRW | 4.75% |
| 2020 Q1 | 11.16 Billion KRW | -13.75% |
| 2020 Q3 | 9.76 Billion KRW | 3.36% |
| 2020 Q2 | 9.45 Billion KRW | -15.34% |
| 2020 FY | 40.6 Billion KRW | -16.13% |
| 2020 Q4 | 10.21 Billion KRW | 4.59% |
| 2019 Q3 | 11.2 Billion KRW | -9.17% |
| 2019 FY | 48.41 Billion KRW | -21.48% |
| 2019 Q1 | 11.91 Billion KRW | -26.85% |
| 2019 Q4 | 12.94 Billion KRW | 15.47% |
| 2019 Q2 | 12.34 Billion KRW | 3.56% |
| 2018 Q2 | 15.75 Billion KRW | -10.46% |
| 2018 Q1 | 17.6 Billion KRW | 10.99% |
| 2018 FY | 61.65 Billion KRW | -8.04% |
| 2018 Q3 | 12 Billion KRW | -23.85% |
| 2018 Q4 | 16.29 Billion KRW | 35.76% |
| 2017 Q1 | 17.22 Billion KRW | -0.07% |
| 2017 Q4 | 15.85 Billion KRW | -3.92% |
| 2017 Q3 | 16.5 Billion KRW | -5.42% |
| 2017 Q2 | 17.45 Billion KRW | 1.29% |
| 2017 FY | 67.04 Billion KRW | -0.62% |
| 2016 Q1 | 16.62 Billion KRW | 5.09% |
| 2016 FY | 67.46 Billion KRW | 9.26% |
| 2016 Q4 | 17.23 Billion KRW | -0.59% |
| 2016 Q3 | 17.34 Billion KRW | 6.64% |
| 2016 Q2 | 16.26 Billion KRW | -2.17% |
| 2015 FY | 61.74 Billion KRW | -1.73% |
| 2015 Q4 | 15.81 Billion KRW | 6.42% |
| 2015 Q3 | 14.86 Billion KRW | -3.91% |
| 2015 Q2 | 15.46 Billion KRW | -0.87% |
| 2015 Q1 | 15.6 Billion KRW | -1.64% |
| 2014 FY | 62.82 Billion KRW | 0.03% |
| 2014 Q1 | 16.9 Billion KRW | 20.29% |
| 2014 Q4 | 15.86 Billion KRW | 4.0% |
| 2014 Q3 | 15.25 Billion KRW | 2.94% |
| 2014 Q2 | 14.81 Billion KRW | -12.33% |
| 2013 Q3 | 15.17 Billion KRW | 0.13% |
| 2013 Q4 | 14.05 Billion KRW | -7.41% |
| 2013 FY | 62.8 Billion KRW | -18.6% |
| 2013 Q1 | 18.42 Billion KRW | -17.35% |
| 2013 Q2 | 15.15 Billion KRW | -17.76% |
| 2012 Q4 | 22.29 Billion KRW | 29.55% |
| 2012 Q2 | 19.01 Billion KRW | 2.03% |
| 2012 FY | 77.16 Billion KRW | 13.15% |
| 2012 Q3 | 17.21 Billion KRW | -9.5% |
| 2012 Q1 | 18.63 Billion KRW | 16.65% |
| 2011 Q4 | 15.97 Billion KRW | -8.61% |
| 2011 Q1 | 17.01 Billion KRW | -4.2% |
| 2011 Q2 | 17.71 Billion KRW | 4.12% |
| 2011 FY | 68.19 Billion KRW | -0.59% |
| 2011 Q3 | 17.48 Billion KRW | -1.32% |
| 2010 FY | 68.59 Billion KRW | -4.02% |
| 2010 Q4 | 17.76 Billion KRW | 9.38% |
| 2010 Q3 | 16.23 Billion KRW | -11.73% |
| 2010 Q2 | 18.39 Billion KRW | 13.54% |
| 2010 Q1 | 16.2 Billion KRW | -11.41% |
| 2009 Q2 | 16.18 Billion KRW | -19.66% |
| 2009 Q3 | 16.85 Billion KRW | 4.16% |
| 2009 Q1 | 20.14 Billion KRW | 3.43% |
| 2009 Q4 | 18.28 Billion KRW | 8.5% |
| 2009 FY | 71.46 Billion KRW | -10.52% |
| 2008 Q4 | 19.47 Billion KRW | 2.34% |
| 2008 Q3 | 19.02 Billion KRW | -6.29% |
| 2008 Q2 | 20.3 Billion KRW | -3.6% |
| 2008 Q1 | 21.06 Billion KRW | 5.71% |
| 2008 FY | 79.87 Billion KRW | 1.32% |
| 2007 FY | 78.83 Billion KRW | 0.0% |
| 2007 Q4 | 19.92 Billion KRW | 14.58% |
| 2007 Q3 | 17.38 Billion KRW | -20.95% |
| 2007 Q2 | 21.99 Billion KRW | 12.71% |
| 2007 Q1 | 19.51 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 43.114% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 93.105% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 87.775% |
| HANDOK Inc. | 522.74 Billion KRW | 85.068% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | 42.342% |
| Yuhan Corporation | 1858.98 Billion KRW | 95.801% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 88.245% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -50.232% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 94.765% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | 42.144% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 78.935% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | 11.897% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | 53.969% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 65.226% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 43.114% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | 48.333% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | 10.657% |
| JW Holdings Corporation | 928.07 Billion KRW | 91.59% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 87.008% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 95.324% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 89.572% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 61.018% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 56.82% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 60.247% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 89.255% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 43.114% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 94.846% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 94.325% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 89.572% |
| Yuhan Corporation | 1858.98 Billion KRW | 95.801% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 90.178% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 66.772% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 86.872% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 89.572% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 73.281% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 72.018% |
| CKD Bio Corp. | 160.35 Billion KRW | 51.324% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 85.188% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 78.385% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 66.122% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 61.018% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 91.128% |
| Boryung Corporation | 859.62 Billion KRW | 90.92% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | 38.018% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 78.935% |
| JW Lifescience Corporation | 206.86 Billion KRW | 62.268% |